Marker Therapeutics Inc(MRKR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.48 | Insider Own | 19.03% | Shs Outstand | 16.7M | Perf Week | -11.5% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -47.75% | Insider Trans | - | Shs Float | 13.5M | Perf Month | -9.09% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.12 | Inst Own | 10.74% | Short Float | 0.81% | Perf Quarter | -10.71% |
| Income | -0.01B | P/S | 7.12 | EPS this Y | 24.89% | Inst Trans | -0.01% | Short Ratio | 1.03 | Perf Half Y | -31.03% |
| Sales | 0.00B | P/B | 1.37 | EPS next 5Y | - | ROA | -59.33% | Short Interest | 0.11M | Perf YTD | -32.89% |
| Book/sh | 0.73 | P/C | 1.4 | EPS past 3/5Y | 39.48% 33.49% | ROE | -76.87% | 52W High | -59.35% ($2.46) | Perf Year | -0.99% |
| Cash/sh | 0.71 | P/FCF | - | Sales past 3/5Y | 0.31% 50.02% | ROIC | -71.57% | 52W Low | 19.05% ($0.84) | Perf 3Y | -61.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 64.88% | Gross Margin | - | Volatility(W/M) | 14.87% 10.56% | Perf 5Y | -93.24% |
| Dividend TTM | - | EV/Sales | 2.03 | Sales Y/Y TTM | -56.64% | Oper. Margin | -458.56% | ATR (14) | 0.12 | Perf 10Y | -98.04% |
| Dividend Ex-Date | - | Quick Ratio | 6.03 | EPS Q/Q | 67.12% | Profit Margin | -372.69% | RSI (14) | 46.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.03 | Sales Q/Q | -100% | SMA20 | -1.45% ($1.01) | Beta | 1.64 | Target Price | $7.87 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/19 | SMA50 | -13.45% ($1.16) | Rel Volume | 0.82 | Prev Close | $0.95 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 29.13% 5.04% | SMA200 | -27.34% ($1.38) | Avg Volume(3M) | 0.11M | Price | $1 |
| IPO | 1998/1/5 | Option/Short | No/Yes | Trades | 214 | Volume | 86,937 | Change | 5.12% |
🔬 Marker Therapeutics is a US clinical-stage immuno-oncology biotech developing a non-genetically-modified **multi-tumor antigen recognition T-cell (MAR-T) platform**. Its lead candidate, **MT-601**, is a MAR-T cell therapy that simultaneously recognizes six tumor antigens, targeting lymphoma patients who have relapsed after CD19 CAR-T failure. Listed on Nasdaq () as a nano-cap stock, clinical data events are the key driver of value.
Over the past 1 year, on the lower side
59% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
MRKR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +24.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $712. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #472 of 594 in the industry
Based on market cap of $17M.
MCRB#471 Seres Therapeutics Inc $18M PER - MRKR#472 Marker Therapeutics Inc $17M PER - 
AKTX#473 Akari Therapeutics Plc ADR $16M PER - 
DYAI#474 Dyadic International Inc, DE $16M PER - 
PLUR#475 Pluri Inc $16M PER - 
FAQ
What kind of company is MRKR?
MRKR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MRKR?
The market cap of MRKR is approximately $17M, ranking 5,271 within its sector.
What is the 52-week high and low for MRKR?
MRKR has recorded a 52-week high of $2.46 and a low of $0.84.
